Liver transplantation for people of minoritised sexual and gender identities in the USA.

The number of people who report to be of minoritised sexual or gender identities in the USA, including lesbian, gay, bisexual, transgender, queer, and other sexuality-diverse and gender-diverse identities, has been increasing in the past decade. This diverse and unique population continues to experience not only health disparities but also psychosocial, economic, and legal disparities in accessing and receiving health care, including liver transplantations. As liver transplantation is life-saving for people with end-stage liver disease, understanding the factors that can affect access to and quality of liver transplantation care in people of minoritised sexual and gender identities in the USA, including differential social supports, insurance coverage, and medical and psychiatric comorbidities, is crucial. Actions, such as collecting sexual orientation and gender identity data, implementing inclusive language, recognising implicit biases, building diverse teams, providing a safer environment, and supporting further research to understand the unique health challenges are needed to ensure equitable access to high-quality liver transplantation care for people of minoritised sexual and gender identities.

Informations de copyright

Copyright © 2023 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests T-HL receives speaker honoraria from Mayo Clinic Arizona and the University of Washington and is a member of the LGBTQ Task Force at the American Association for the Study of Liver Diseases, of the executive board of Rainbows in Gastro, of the Liver and Intestinal Community of Practice, of the American Society of Transplantation, and of the Diversity, Equity, and Access to Life Committee of the American Society of Transplantation. ND is an executive board member of Rainbows in Gastro. KS receives funding from the US National Institutes of Health (K08 DK132509–01A1); receives speaker honorarium from Satellite Healthcare; is a board member of the American Living Organ Donor Fund; and holds stock in GE Healthcare, Gilead, and Johnson & Johnson. DAS receives consulting fees, paid to their institution, from Mallinckrodt and BioVie; holds patent 18/151,673; and is a member of the executive board of Rainbows in Gastro. SP receives funding from Intercept, Target PharmaSolutions, and Genfit; is a member of the Diversity, Equity, and Inclusion Committee of the American Gastroenterological Association, of the diversity committee of the American College of Gastroenterology, of the LGBTQ Task Force of the American Association for the Study of Liver Diseases, and of the executive board of Rainbows in Gastro.